These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 34622569)
1. Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review. Imakita T; Fujita K; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T Thorac Cancer; 2021 Nov; 12(22):3062-3067. PubMed ID: 34622569 [TBL] [Abstract][Full Text] [Related]
2. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Tomic K; Krpina K; Baticic L; Samarzija M; Vranic S J Drug Target; 2024 Jun; 32(5):499-509. PubMed ID: 38506620 [TBL] [Abstract][Full Text] [Related]
4. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033 [TBL] [Abstract][Full Text] [Related]
6. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report. Wu CH; Su PL; Hsu CW; Chu CY; Lin CC Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764 [TBL] [Abstract][Full Text] [Related]
7. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048 [TBL] [Abstract][Full Text] [Related]
8. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Tokaca N; Wotherspoon A; Nicholson AG; Fotiadis N; Thompson L; Popat S Lung Cancer; 2017 Sep; 111():65-68. PubMed ID: 28838401 [TBL] [Abstract][Full Text] [Related]
9. Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review. Clamon G; Zeitler W; An J; Hejleh TA Am J Clin Oncol; 2020 Sep; 43(9):670-675. PubMed ID: 32889839 [TBL] [Abstract][Full Text] [Related]
10. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668 [TBL] [Abstract][Full Text] [Related]
11. [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. Zhang W; Li Y; Wu D Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):720-726. PubMed ID: 29061221 [TBL] [Abstract][Full Text] [Related]
12. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864 [TBL] [Abstract][Full Text] [Related]
13. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887 [TBL] [Abstract][Full Text] [Related]
14. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. Yamada T; Azuma K; Muta E; Kim J; Sugawara S; Zhang GL; Matsueda S; Kasama-Kawaguchi Y; Yamashita Y; Yamashita T; Nishio K; Itoh K; Hoshino T; Sasada T PLoS One; 2013; 8(11):e78389. PubMed ID: 24223798 [TBL] [Abstract][Full Text] [Related]
15. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684 [TBL] [Abstract][Full Text] [Related]
17. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851 [TBL] [Abstract][Full Text] [Related]
18. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528 [TBL] [Abstract][Full Text] [Related]
19. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy. Zeng J; Ding X; Ding J; Wang X Front Immunol; 2023; 14():1275957. PubMed ID: 38022621 [TBL] [Abstract][Full Text] [Related]
20. A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity. Xu Y; Huang Z; Gong L; Fan Y Anticancer Drugs; 2017 Oct; 28(9):1056-1061. PubMed ID: 28723866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]